Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778731 | 0.83 | RIPK1 (0.39) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1779933 | 0.77 | DRD2 (0.44) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1777680 | 0.73 | RIPK1 (0.60) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778988 | 0.72 | RIPK1 (0.49) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1777852 | 0.71 | RIPK1 (0.49) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778783 | 0.70 | RIPK1 (0.48) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778695 | 0.69 | RIPK1 (0.46) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1779504 | 0.69 | IGF1R (0.47) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1777443 | 0.69 | RIPK1 (0.46) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778453 | 0.68 | RIPK1 (0.45) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |